CFB
KRYS icon

Cullen/Frost Bankers’s Krystal Biotech KRYS Stock Holding History

Cullen/Frost Bankers’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-187
Closed -$48.3K – 1455
2026
Q1 		$48.3K Buy
+187
New +$49.8K ﹤0.01% 814
2025
Q1 		– Sell
-32
Closed -$5.01K – 1404
2024
Q4 		$5.01K Buy
32
+4
+14% +$710 ﹤0.01% 1005
2024
Q3 		$5.1K Buy
28
+4
+17% +$771 ﹤0.01% 1004
2024
Q2 		$4.41K Buy
+24
New +$4.03K ﹤0.01% 972

Other funds holding KRYS

Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $153M AUM
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $79.3B AUM 43.63% 1-Year Est. Return
HP
HealthInvest Partners Stockholm, Sweden $372M AUM 59.89% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $54.2B AUM 43.77% 1-Year Est. Return
MIF
Mediolanum International Funds Dublin 1, Ireland $11.7B AUM 47.18% 1-Year Est. Return
SOADOR
State of Alaska Department of Revenue Juneau, Alaska $10.1B AUM 42.83% 1-Year Est. Return
TIP
Torray Investment Partners Bethesda, Maryland $741M AUM 26.16% 1-Year Est. Return

Cullen/Frost Bankers's KRYS Position: Q2 2026 in Review

Cullen/Frost Bankers sold out of Krystal Biotech (KRYS) in Q2 2026, closing a stake of 187 shares — an estimated $48.3K sold.

Cullen/Frost Bankers first reported a position in KRYS in Q2 2024 and held it in 4 quarters. The position peaked at $48.3K in Q1 2026. 109 funds tracked by Wall St. Rank hold KRYS as of Q2 2026.

  • Cullen/Frost Bankers reported no remaining Krystal Biotech position as of Q2 2026 after selling out during the quarter.
  • Cullen/Frost Bankers sold 187 Krystal Biotech shares in Q2 2026, an estimated $48.3K.
  • Cullen/Frost Bankers first reported a position in Krystal Biotech in Q2 2024 and held it in 4 quarters.
  • Cullen/Frost Bankers's Krystal Biotech position peaked at $48.3K in Q1 2026.
  • 109 funds tracked by Wall St. Rank held Krystal Biotech as of Q2 2026.

Based on Cullen/Frost Bankers's 13F filing for Q2 2026, filed 27 Jul 2026.